XML 40 R20.htm IDEA: XBRL DOCUMENT v3.20.2

Revenues (Tables)

6 Months Ended

Jun. 30, 2020

Segment Reporting [Abstract]

Summary of net revenue

The Company’s net revenues consisted of the following for the three and six months ended June 30, 2020 and 2019:

			Three months ended June 30,																		Six months ended June 30,
			2020						2019						2020						2019
Products:
Acetadote			$	595,310					$	983,473					$	1,308,711					$	1,832,976
Omeclamox-Pak			10,948						478,604						124,371						678,141
Kristalose			3,477,471						3,476,807						6,771,433						6,785,050
Vaprisol			174,159						212,526						382,016						499,202
Caldolor			1,166,569						1,054,718						2,261,286						2,372,599
Vibativ			3,299,507						2,599,280						5,721,708						4,659,471
Other revenue			874,213						612,035						1,359,386						1,319,864
Total net revenues			$	9,598,177					$	9,417,443					$	17,928,911					$	18,147,303

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration